secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0001104659-23-106149
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics updates investor deck highlighting pipeline, Allo-Evasion 3.0, and cash runway into 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $301M at Q2 2023; runway extends into 2026.
- ELiPSE-1 trial for CNTY-101 (iNK CD19) ongoing; initial data expected by end of 2023, PoC in 2024.
- Pipeline includes CNTY-102 (iT CD19/CD22 dual-target) and CNTY-107 (iT Nectin-4); BMS collaboration for CNTY-104 (AML) and CNTY-106 (myeloma).
- Allo-Evasion 3.0 incorporates 4 edits (β2M KO, CIITA KO, HLA-E KI, HLA-G KI) to protect against NK cell killing.
- CNTY-101 designed with Allo-Evasion to enable repeat dosing without additional lymphodepletion; first CD19 agent with this approach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923106149/0001104659-23-106149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923106149/tm2327303d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-106149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer